Cardiometabolic health, visceral fat and circulating irisin levels: results from a real-world weight loss study

T. Miazgowski1 · A. Kaczmarkiewicz2 · B. Miazgowski2 · J. Kopeć3

Received: 12 August 2020 / Accepted: 31 August 2020 / Published online: 6 September 2020
© The Author(s) 2020

Abstract
Background The aim of this pragmatic intervention study was to investigate changes in cardiometabolic outcomes, irisin plasma concentration, and body composition during a 4-month intervention in unselected obese individuals.

Materials and methods In 111 obese women aged 36.73 ± 7.2 years, we measured changes in weight, lipid profiles, glucose, insulin, Homeostatic Model Assessment-Insulin Resistance Index (HOMA-IR), uric acid, aminotransferases, and irisin. Body composition including lean mass (LM) and total (TF), gynoid (GF), android (AF), and visceral fat (VF) was assessed using densitometry. Physical activity was assessed using the International Physical Activity Questionnaire (IPAQ). The participants received tailored written advice targeting lifestyle according to current guidelines. At follow-up, patients rated their adherence in the self-administered questionnaire.

Results Mean weight loss in the whole group was 3.12 kg (−3.3%); 26% of the women achieved the desired target of weight loss (>5% of the initial weight), whereas weight decreased moderately in 50% and increased in 14%. In 86 women with weight loss, there were significant changes in HOMA-IR (−13.8%), insulin (−11.2%), alanine aminotransferase (−8.0%), VF (−7.0%), AF (−5.4%), TF (−4.7%), GF (−2.8%) and LM (−1.5%), whereas irisin and HDL-C levels and the mean IPAQ score did not change.

Conclusions In this real-world evidence study, a successful weight loss achieved only 26% of patients, with overall much better adherence to diet restriction than to exercise. However, even mild to moderate weight loss resulted in significant improvements in cardiometabolic health. Weight loss was associated with a modest LM decrease but did not influence plasma irisin.

Keywords Cardiometabolic health · Weight loss · Irisin · Real-world study

Introduction
It has been well-documented that weight loss in obese individuals lowers cardiometabolic risks, reduces the prevalence and burden of obesity-related comorbidities, and improves overall health. These beneficial changes are driven mainly by changes in body composition: reduction of fat mass and its redistribution. Current guidelines define the desired target as at least 5% weight reduction within the first 6 months of intervention [1, 2]. However, the guidelines are based mainly on data from reference studies performed in selected populations, in which dietary regimens and the level of exercising are usually pre-defined and strictly monitored during the intervention. Much less is known about how effective weight management techniques are in clinical practice. In real-world settings, weight loss frequently does not meet recommended targets [3, 4] and hence, metabolic benefits resulting from weight loss may be less apparent.

Irisin—an exercise-induced myokine produced by proteolytic cleavage of fibronectin type III domain-containing protein 5 (FNDC5)—is involved in the regulation of energy metabolism by activating thermogenesis [5]. In animal models, exogenous irisin showed an anorexigenic effect in rodents suggesting its inhibitory role in the central control of food intake [6, 7]. In addition, the myokine promoted
β-cell survival and insulin secretion [8]. Studies of other effects of this myokine in humans have yielded conflicting results. Some but not all reports suggested a possible role of irisin in the modulation of glucose [9, 10] and lipid metabolism [11, 12] as well as its correlation with weight, surrogate measures of adiposity such as BMI and waist circumference (both negative [14] and positive [15]), and level of physical activity [16]. Based on these suggestions we hypothesized that in obese individuals, life style improvement and weight reduction might influence plasma levels of this myokine.

The aim of this pragmatic intervention study, based on a single-mode lifestyle counselling common in routine clinical practice, was to investigate changes in cardiometabolic outcomes, irisin plasma concentration, and body composition during a 4-month intervention in unselected obese individuals. Among the body composition parameters, we focused on visceral fat — a key contributor to unfavorable changes in glucose and lipid metabolism, as well as lean mass, whose reduction has been suggested to be a detrimental effect of weight loss programs [17, 18].

Materials and methods

Study participants

Study participants were recruited from obese patients consecutively admitted for the first time to our outpatient secondary care unit for the treatment of obesity and metabolic disorders over a 1-year period. Patients with coexisting hypertension, dyslipidemia, hyperuricemia, type 2 diabetes, arthritis, and hypothyroidism received standard treatments. None of the patients received insulin, glucocorticoids, or protein supplements. In individual cases, patients took selenium, zinc, vitamin D, and herbal supplements. The study complied with all applicable institutional regulations regarding the ethical use of human volunteers in research and the terms of the Declaration of Helsinki. The Pomeranian Medical University Ethics Committee approved the study protocol, and all participants gave their written consent.

The study protocol included two visits: baseline and follow-up after 4–5 months. At the baseline visit, during an approximately 2-h session with a doctor and a trained dietician, participants were encouraged to implement healthier behaviors and received written advice targeting lifestyle modification according to current guidelines [1, 2]. Total daily energy requirements were calculated from basal metabolic rates and levels of physical activity (PA), and then reduced by 500–800 kcal per day. Weekly menus were prepared using a dietary calculator ALIANT (available at: https://alian.com.pl), which includes recommended dietary allowance of micro- and macro elements. Moderate or moderate-to-vigorous PA for at least 30 min a day three or more days per week was recommended [19]. Both dietary regimen and the level of PA were tailored to patients’ individual habits, preferences, and needs. During both visits, anthropometric indices, laboratory tests, body composition, and physical activity were assessed.

Anthropometric and biochemical measures

We measured height (at the baseline visit only) and weight, waist, hip, and neck circumferences (at both visits). Biochemical analyses encompassed fasting glucose, insulin, lipid profiles (triglycerides, total cholesterol and its LDL-C and HDL-C fractions), uric acid, aminotransferases (alanine; ALT and asparagine; AST), and irisin. Plasma irisin was assessed by ELISA using recombinant antibodies (Irisin Recombinant Human, Mouse, Rat, Canine; Phoenix Pharmaceuticals Inc., USA; catalog No. EK-067-29; the intra- and inter-assay variations were < 10% and < 15%, respectively; normal range provided by the manufacturer: 5.8–23.2 ng/ml). From fasting insulin and glucose, a Homeostatic Model Assessment-Insulin Resistance Index (HOMA-IR) was calculated, assuming a value of HOMA-IR < 2.5 as normal. We also calculated β-cell function (HOMA-%B). HOMA-IR and HOMA-%B were calculated using the HOMA Calculator v2.2.3 available at www.dtu.ox.ac.uk.ac.uk. Concomitant arterial hypertension, prediabetes/diabetes type 2, and abnormal values of waist circumference, blood lipids, HOMA-IR, uric acid, and ALT were considered to be cardiometabolic risk factors (CMRFs).

Body composition

Body composition was assessed using dual-energy X-ray absorptiometry (DXA) (GE Healthcare Lunar Prodigy Advance; Madison, WI, USA) using the automatic whole-body scan mode. We analyzed total (TF), android (AF), and gynoid (GF) fat, as well as lean mass (LM), which in DXA is a surrogate measure of muscle mass. Visceral fat (VF) was computed using a GE Healthcare DXA device with the dedicated CoreScan® application.

Physical activity

The International Physical Activity Questionnaire (IPAQ) was used to assess the self-reported level of habitual PA. The IPAQ questionnaire comprises seven questions related to different types of PA undertaken in a period of 7 days prior to completing the questionnaire. Total PA was categorized as low (< 600 METs min/week), moderate (600–3000 METs min/week), or vigorous (> 3000 METs min/week) [20].

 Springer
**Self-assessment of adherence**

At follow-up, patients were asked to what extent they adhered to the weight loss intervention, with three possible responses: ‘rather not’, ‘rather yes’ and ‘definitely yes’.

**Statistical analyses**

Descriptive statistics included mean ± standard deviation (SD) for continuous variables and frequency distributions for categorical variables. Variables with a normal distribution were compared using paired Student’s *t* tests; otherwise, non-parametric Mann–Whitney *U*-tests and Kruskal–Wallis tests were used. Differences in study outcomes between patients with successful and modest weight loss, and without weight loss were compared using ANOVA; *p* for trend across categories was calculated using Cochran-Armitage test for trend. Correlations between pairs of quantitative variables were assessed using Pearson’s linear correlations or Spearman’s *ρ* correlations for normally and non-normally distributed variables, respectively. The associations of body composition (predictors) with CMRFs (outcomes) were assessed using multiple linear regression models adjusted for BMI, age, and lipid-lowering, hypoglycemic, hypouricemic, and antihypertensive treatments. Due to multicollinearity among DXA-derived body composition parameters (the variance inflation factor > 10), predictors of weight loss were calculated using ridge regression [21]. The *λ* value (the Lagrange multiplier which controls the strength of the penalty term and minimizes mean square error) of 37.41 was included in the final model. The results of regression analyses were expressed as coefficient estimates (*β*R).

**Results**

**Baseline characteristics**

The study sample included 111 obese women aged 36.73 ± 7.2 years (range: from 19 to 49 years). At the baseline visit (Table 1), patients were taking medications for dyslipidemia (65%), hyperuricemia (27%), hypertension (23%), and type 2 diabetes (2%). Baseline laboratory tests revealed a high frequency of elevated HOMA-IR (69%), LDL-C (63%), total cholesterol (42%), and low HDL-C (37%). Hypertriglyceridemia and elevated ALT activity were also frequent. In patients with comorbidities, routine pharmacological treatments remained unchanged during the entire study period.

**Follow-up**

Follow-up was performed after a median of 4.0 months (range: from 3.1 to 5.2 months). The mean weight loss in the whole group was 3.12 ± 1.2 kg (− 3.3%). However, only 29 women (26%) achieved the desired target of weight loss (5% or greater of the initial weight), whereas weight decreased moderately in 50% of the women and increased in 14% (Table 2). In the self-administered questionnaire, 43 patients (39%; mean weight change -6.6%; 95% CI: − 8.9% to − 4.2%) rated their adherence to lifestyle modification as ‘definitely yes’, 56 (50%; weight change − 2.4%; − 5.1% to 0.3%) as ‘rather yes’, and 12 (11%) as ‘rather not’ (all with weight gain).

Overall, 97 women (87.3%) lost weight by an average of 3.9 kg. As shown in Table 3, weight loss was accompanied by significant reductions in all anthropometric indices, results of laboratory tests, and body composition parameters. Among the latter, the greatest reductions were in VF.

---

**Table 1** Baseline characteristics of study participants

|                  | N  | %   |
|------------------|----|-----|
| Data from medical history |    |     |
| Arterial hypertension   | 26 | 23  |
| Type 2 diabetes         | 3  | 3   |
| Dyslipidemia            | 72 | 65  |
| Gallbladder diseases    | 15 | 14  |
| Arthritis               | 2  | 2   |
| Hyperuricemia           | 30 | 27  |
| Hypothyroidism          | 9  | 8   |
| Baseline laboratory findings |   |     |
| Fasting glucose > 125 mg/dl | 1 | 1   |
| Fasting glucose 100–125 mg/dl | 18 | 16  |
| HOMA-IR ≥ 2.5          | 76 | 69  |
| Total cholesterol > 200 mg/dl | 47 | 42  |
| LDL-C ≥ 115 mg/dl        | 70 | 63  |
| HDL-C ≤ 50 mg/dl         | 41 | 37  |
| Triglycerides ≥ 150 mg/dl | 29 | 26  |
| Uric acid > 6 mg/dl      | 22 | 20  |
| ALT > 35 U/l            | 20 | 18  |
| AST > 32 U/l            | 8  | 7   |

**Table 2** Distribution of weight change

|                  | n   | Weight change (kg) | Range (kg) |
|------------------|-----|--------------------|------------|
| All              | 111 (100%) | − 3.12 ± 2.14      | − 19.9 to 6.33 |
| Referent (> 5%)  | 29 (26%)   | − 7.34 ± 2.21      | − 19.9 to − 5.19 |
| Moderate (< 5%)  | 68 (61%)   | − 3.01 ± 1.22      | − 4.71 to − 0.72 |
| No weight loss   | 14 (13%)   | 2.52 ± 1.99        | 0.36 to 6.33  |
### Table 3

Changes in anthropometric measures, laboratory tests, body composition, and physical activity between baseline and follow-up

| Measure                  | Baseline          | Follow-up         | % Change | P     |
|--------------------------|-------------------|-------------------|----------|-------|
| **Anthropometric measures** |                   |                   |          |       |
| Weight (kg)              | 95.23 ± 14.58     | 92.11 ± 14.17     | − 3.3    | < 0.001 |
| (70.0–139.8)             | (67.4–135.2)      |                   |          |       |
| Body mass index (kg/m²)  | 34.83 ± 4.27      | 33.75 ± 4.22      | − 3.1    | < 0.001 |
| (30.0–47.9)              | (28.2–47.3)       |                   |          |       |
| Waist (cm)               | 108.7 ± 10.79     | 104.9 ± 10.98     | − 3.5    | < 0.001 |
| (86.0–142.0)             | (73.5–137.0)      |                   |          |       |
| Hip (cm)                 | 118.9 ± 9.86      | 115.32 ± 9.63     | − 3.0    | < 0.001 |
| (102.0–149.0)            | (92.5–142.0)      |                   |          |       |
| Neck (cm)                | 37.98 ± 2.71      | 37.20 ± 2.75      | − 2.1    | < 0.001 |
| (31.5–46.0)              | (30.8–45.0)       |                   |          |       |
| **Laboratory tests**     |                   |                   |          |       |
| Glucose (mg/dl)          | 92.05 ± 10.48     | 89.59 ± 9.43      | − 2.7    | < 0.001 |
| (69.4–138.5)             | (68.1–117.2)      |                   |          |       |
| Insulin (μIU/ml)         | 16.06 ± 9.33      | 14.26 ± 7.95      | − 11.2   | < 0.001 |
| (3.7–73.7)               | (2.3–68.5)        |                   |          |       |
| HOMA-IR                  | 3.71 ± 2.39       | 3.20 ± 2.00       | − 13.8   | < 0.001 |
| (0.8–19.8)               | (0.5–17.9)        |                   |          |       |
| HOMA-%B                  | 148.2 ± 36.7      | 142.7 ± 32.6      | − 1.03   | 0.342  |
| (100.0–177.1)            | (87.8–189.1)      |                   |          |       |
| Total cholesterol (mg/dl)| 191.51 ± 34.07    | 183.64 ± 31.48    | − 4.1    | < 0.001 |
| (119.4–298.2)            | (112.9–281.9)     |                   |          |       |
| LDL-C (mg/dl)            | 127.28 ± 31.88    | 121.35 ± 29.81    | − 4.7    | < 0.001 |
| (53.0–232.0)             | (57.0–211.7)      |                   |          |       |
| HDL-C (mg/dl)            | 54.53 ± 14.25     | 55.23 ± 13.45     | 1.3      | 0.189  |
| (30.0–98.8)              | (30.4–100.0)      |                   |          |       |
| Triglycerides (mg/dl)    | 133.96 ± 74.66    | 124.48 ± 65.55    | − 7.1    | < 0.001 |
| (42.4–434.0)             | (39.5–404.5)      |                   |          |       |
| ALT (U/l)                | 25.02 ± 15.54     | 23.01 ± 14.04     | − 8.0    | < 0.001 |
| (6.0–96.0)               | (5.5–88.3)        |                   |          |       |
| AST (U/l)                | 21.66 ± 11.89     | 20.37 ± 11.15     | − 6.0    | < 0.001 |
| (8.0–97.0)               | (7.5–91.1)        |                   |          |       |
| Uric acid (mg/dl)        | 5.17 ± 1.02       | 4.97 ± 0.91       | − 3.9    | < 0.001 |
| (3.2–8.4)                | (3.4–8.0)         |                   |          |       |
| Irisin (ng/ml)           | 12.85 ± 17.31     | 11.63 ± 12.33     | − 9.5    | 0.193  |
| (5.9–136.1)              | (5.5–117.0)       |                   |          |       |
| **Body composition**     |                   |                   |          |       |
| Total fat (kg)           | 43.86 ± 10.16     | 41.82 ± 10.10     | − 4.7    | < 0.001 |
| (25.4–75.1)              | (24.2–71.7)       |                   |          |       |
| Total fat (%)            | 47.19 ± 4.97      | 45.88 ± 5.26      | − 2.8    | < 0.001 |
| (35.4–59.2)              | (30.6–59.4)       |                   |          |       |
| Android fat (kg)         | 7.60 ± 1.47       | 7.19 ± 1.38       | − 5.4    | < 0.001 |
| (5.1–11.7)               | (4.8–10.6)        |                   |          |       |
| Gynoid fat (kg)          | 15.16 ± 2.52      | 14.74 ± 2.48      | − 2.8    | < 0.001 |
| (10.5–22.0)              | (10.2–22.7)       |                   |          |       |
| Visceral fat (kg)        | 1.36 ± 0.57       | 1.28 ± 0.54       | − 5.9    | < 0.001 |
| (0.2–2.9)                | (0.2–2.7)         |                   |          |       |
| Visceral fat (cm³)       | 1446 ± 600        | 1345 ± 577        | − 7.0    | < 0.001 |
| (220–3035)               | (205–2821)        |                   |          |       |
| Lean mass (kg)           | 50.79 ± 5.76      | 50.03 ± 5.43      | − 1.5    | 0.01   |
| (38.5–68.7)              | (38.1–65.1)       |                   |          |       |
mass (− 6%) and volume (− 7%). VF reduction was greater than reductions in TF, AF, and GF. Importantly, LM also slightly but significantly decreased (by 1.5%). At baseline, the majority of women declared moderate PA (600–3000 MET-min/week); however, a noticeable percentage (24%) rated it as low (< 600 MET-min/week). At follow-up the mean IPAQ score and the number of women with moderate or vigorous PA tended to increase; however, these changes did not reach statistical significance.

In ridge regression, the magnitude of weight loss was associated with reductions in TF ($\beta_R = 15.8; p < 0.001$), AF ($\beta_R = 9.91; p = 0.003$) and GF ($\beta_R = 8.43; p = 0.021$), whereas associations with VF mass and LM were not significant.

As summarized in Table 4, surrogate measures of adiposity (BMI, neck, waist, and hip circumference) tended to correlate with CMRFs. Neck circumference showed the strongest correlations with CMRFs, particularly with HOMA-IR, insulin, glucose, HDL-C, and uric acid. Neck circumference was positively correlated with waist ($r = 0.590$) and hip circumference ($r = 0.378$). In contrast to other anthropometric measures, neck circumference also correlated with LDL-C and triglycerides.

Among DXA-derived body composition parameters, VF was a positive correlate of CMRFs, particularly glucose, HOMA-IR, triglycerides and uric acid, and these correlations were stronger than those of TF, AF and GF. Similarly, in multiple linear regression models adjusted for BMI, age, and lipid-lowering, hypoglycemic, hypouricemic and anti-hypertensive treatments, VF was positively associated with HOMA-IR ($\beta = 0.42; p < 0.001$) and uric acid ($\beta = 0.39; p = 0.003$), whereas the associations were weaker for TF ($\beta = 0.30; p = 0.009$ and $\beta = 0.19; p = 0.041$, respectively) and AF ($\beta = 0.36; p = 0.004$ and $\beta = 0.31; p = 0.006$, respectively), and non-significant for GF.

As expected, the beneficial changes in laboratory CMRFs (Fig. 1) and body composition (Fig. 2) significantly differed between groups with and without weight loss in a dose–response manner. In those without weight loss, insulin, HOMA-IR and ALT significantly increased (by 6.7%, 7.2%, and 7.1%, respectively; all $p < 0.05$ vs. baseline). Other obesity measures tended to increase, particularly VF (by 4.4% vs. baseline), but these changes were not significant. The mean IPAQ score did not differ between women with a weight reduction of at least 5% and those whose weight did not decrease during the study period.

**Irisin**

Irisin plasma levels were within the reference range and did not differ between baseline and follow-up (Table 3). In the analysis of all results combined from samples collected at baseline and follow-up (Table 4), irisin showed weak but significant positive correlations with weight, BMI, neck and waist circumferences, LM, and GF. Irisin was also positively correlated with insulin ($r = 0.202; p = 0.002$) and HOMA-IR ($r = 0.184; p = 0.006$). Although irisin was weakly correlated with weight, changes in weight did not influence irisin levels (Fig. 1). No correlations were found between irisin and other parameters of body composition, blood lipids, and the IPAQ score.

**Discussion**

In this real-world intervention that was based on a single-mode lifestyle counseling given to non-selected obese women, the desirable goal of weight loss > 5% of initial value was achieved by 26% of participants. As expected, cardiometabolic improvements from weight loss increased in a dose–response manner. However, even mild to moderate weight reduction in the order of 3–4%, as found in our study, was associated with measurable beneficial cardiometabolic effects, including significant reductions in anthropometric indices (BMI and waist, hip and neck circumference), glucose, total cholesterol, LDL-C, ALT (a biomarker of fatty liver disease [22]), triglycerides, aminotransferases, and uric acid. The greatest reductions were seen for insulin levels and HOMA-IR (− 11% and − 14%, respectively). Among the DXA-derived body composition parameters, VF was the strongest positive correlate of blood lipids, insulin resistance, and uric acid level.

Earlier studies of these associations were often hampered by insufficient methodology for quantifying visceral adipose tissue content, specifically, using indirect VF measurements.
such as sagittal abdominal diameter, waist circumference or waist-to-hip-ratio. Imaging techniques such as computed tomography or magnetic resonance imaging (MRI) accurately quantify VAT but these techniques are costly, time-consuming, or associated with a risk of radiation. We report here for the first time the association of 
VF and serum uric acid level using quantification of VF by DXA. This modality measures VF with high precision and has demonstrated a strong correlation with VF measured by computed tomography and MRI [23]. Similarly to our results, Rospleszcz et al. [24] recently found an association of VF with uric acid ($\beta = 0.55$) in overweight individuals using MRI. Altogether, these findings confirm that VF mass influences not only insulin sensitivity, lipid profiles, and function of the liver, but also purine metabolism.

Although it has been demonstrated that exercise can play a role in both short- and long-term weight loss and weight maintenance [1, 19], in routine practice it is often challenging for patients to engage in a regular exercise program and to continue that program as a lifestyle modification [25]. This issue also pertains to our study. Although we tailored exercise recommendations to an individual’s preferences and habitual PA, adherence to exercise was relatively weak. The mean IPAQ score and the number of women with moderate to vigorous PA tended to increase, but this trend was not statistically significant. In addition, IPAQ was not correlated with weight or changes in other anthropometric indices suggesting that PA played a minimal role in weight loss. These findings are supported by a recent report in which a hypocaloric diet without prescription of physical activity was sufficient to lose weight in the short term [26].

As expected, weight loss was associated with a reduction of TF and its two main compartments: AF and GF. However, the greatest reductions occurred in VF mass and volume. Although VF is a relatively small fat depot (in this study it comprised only 1.4% of body weight and 3% of TF), but due to its high lipolytic activity and ability to release inflammatory cytokines, it has been found to be a robust predictor of cardiovascular disease [27, 28]. Previous studies have demonstrated the effectiveness of non-pharmacological methods for VF reduction using diet alone or in combination with aerobic exercise or high-intensity interval training [26, 29–31]. Our results strongly suggest that lifestyle modification based on dietary restriction combined with modest PA can be an effective approach to reducing VF mass and volume.

Another finding of this study is the diminution of LM in weight loss programs. Following the intervention, we found LM to be reduced by approximately 0.75 kg (1.5% of the initial mass), but this reduction did not contribute substantially to overall weight loss. The value of this finding may be weakened by some methodological concerns regarding the assessment of LM by DXA. Although DXA-LM is mainly composed of muscles, LM is not a
direct measure of muscle mass because this compartment contains also other tissues such as blood, skin, tendons and viscera, and the volume of all these tissues can be influenced by hydration status, which may change with age, exercise, weight loss and other factors. In addition, a recent study demonstrated a wide variation in the correlation between DXA and MRI (the reference modality) in the regional muscle mass quantification, from 0.26 in the trunk do 0.88 in legs [32]. Furthermore, from studies evaluating changes in structural features and composition of the skeletal muscle using computed tomography and MRI [33, 34] it can be assumed that weight gain and low PA lead to increases in intramuscular adipose tissue (IMAT) content, which infiltrates skeletal muscle fibers and is functionally considered an ectopic fat depot [35]. As DXA-LM does not quantify IMAT, we speculate that LM reduction in our study might be driven, at least partially, by a decrease in IMAT corresponding to changes in total and regional fat, and possibly also other ectopic fat depots. Consequently, a true muscle wasting effect would be negligible. Therefore, LM reduction is often only modest and of no substantial effect on overall weight loss. Such interpretation could be applied also to other studies reporting modest LM reductions in response to weight loss [36].
The relationship of plasma irisin concentration with chronic exercise training or habitual PA is controversial as both increasing [37] and decreasing [38] levels of this myokine have been observed. Likewise, contradictory evidence has been shown associating irisin levels with CMRFs, including blood lipids, anthropometric parameters, and fat mass [14, 15, 39]. In our study, circulating irisin was correlated with adiposity measures but, in general, these correlations were weak. We also found a slightly stronger correlation with insulin and HOMA-IR. On the other hand, similarly to Fukushima et al. [9], we did not find irisin to be associated with weight loss. To our knowledge, in only one study caloric restriction has been shown to decrease circulating irisin levels, with a subsequent increase if the weight was regained [13]. However, the population sampled in this study had a higher baseline BMI (35.8 kg/m²) and insulin concentration (13.6 μIU/ml), and greater weight loss (-6.1 kg) over time. Importantly, they also used a different assay to measure irisin. The key point of explaining these discrepancies may be related to insulin sensitivity. Many studies, including our report of a positive associations of irisin with HOMA-IR [10, 39, 40], suggest that it is not body weight per se but rather the level of insulin resistance that predisposes the individual to a higher irisin concentration. However, it is unclear whether this phenomenon represents exclusively a compensatory increase of irisin to overcome an underlying irisin resistance in both obese and non-obese subjects.

Our results may have some methodological limitations. Firstly, some researchers have questioned the reliability of circulating irisin levels measured with commercial ELISA assays due to still unresolved issue of transcription of the irisin precursor FNDC5 gene across species, the high levels of inter- and intra-assay variation with these assays, and the large reported range of irisin levels (0.02–4300 ng/ml) [41]. Secondly, the accuracy of DXA-LM measurement can be affected by hydration status. To minimize this effect, all patients DXA scans were performed in the morning after an overnight fast. Thirdly, the results of body composition in this study may not be reproducible using a different DXA machine and software. Finally, patients in this study were taking medications for comorbidities that might affect the study outcomes, particularly biochemical CMRFs. However, all treatments were stable during the entire study period; therefore, they should not affect the reported changes in outcomes over time.

In conclusion, in this real-world evidence study, lifestyle modification in obese women resulted in successful (>5%) weight loss in 26% of patients, with overall much better adherence to diet restriction than to exercise. However, even mild to moderate weight loss resulted in significant improvements in cardiometabolic health. Weight loss was associated with a decrease in VF mass and a modest LM decrease but did not influence plasma irisin levels.

Acknowledgements This work was supported by the Pomeranian Medical University (Grant for Young Researchers No. MB-315-201/16) and Polish Osteoporosis Foundation BO in Szczecin.

Compliance with ethical standards
Conflict of interest All authors declare that they have no conflict of interest.

Ethical approval The study complied with all applicable institutional regulations regarding the ethical use of human volunteers in research and the terms of the Declaration of Helsinki. The Pomeranian Medical University Ethics Committee approved the study protocol.

Informed consent All participants gave their written consent.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References
1. Jensen MD, Ryan DH, Apowian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society (2014) 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation 129(25 Suppl. 2):S102–S138
2. Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines (2016) American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract 22(7):842–884
3. Primack C (2018) A review and critique of published real-world weight management program studies. Postgr Med 130(6):548–560
4. Dudekula A, Rachakonda V, Shaik B, Behari J (2014) Weight loss in nonalcoholic fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PLoS ONE 9(11):e111808
5. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hejlund K, Gygi SP, Spiegelman BM (2012) A PGC1-α-dependent myokine that...
drives brown-fat-like development of white fat and thermogenesis. Nature 481(7382):463–468
6. Natalichio A, Marrano N, Biondi G, Dipaola L, Spagnuolo R, Cignarelli A, Perrini S, Laviola L, Giorgino F (2020) Irisin increases the expression of anorexigenic and neurotrophic genes in mouse brain. Diabetes Metab Res Rev 36(3):e2328
7. Ferrante C, Orlando G, Recinella L, Leone S, Chiavaroli A, Di Nisco C, Shohreh R, Maniipa F, Ricciuti A, Vacca M, Brunetti L (2016) Central inhibitory effects on feeding induced by the adipokine irisin. Eur J Pharmacol 791:389–394
8. Natalichio A, Marrano N, Biondi G, Spagnuolo R, Labarbata R, Porreca I, Cignarelli A, Bugliani M, Marchetti P, Perrini S, Laviola L, Giorgino F (2017) The myokine irisin is released in response to saturated fatty acids and promotes pancreatic β-cell survival and insulin secretion. Diabetes 66(11):2849–2856
9. Fukushima Y, Kurose S, Shiono H, Cao Thi Thu H, Tamanoi M, Tsutsumi H, Hasegawa T, Nakajima T, Kimura Y (2016) Relationships between serum irisin levels and metabolic parameters in Japanese patients with obesity. Obes Sci Pract 2:203–209
10. Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, Tsoukas MA, Geladari EV, Huh JY, Dincer F, Davis CR, Crowell JA, Mantzoros CS (2013) Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98(12):4899–4907
11. Tang S, Zhang R, Jiang F, Wang J, Chen M, Peng D, Yan J, Wang S, Bao Y, Hu C, Jia W (2015) Circulating irisin levels are associated with lipid and uric acid metabolism in a Chinese population. Clin Exp Pharmacol Physiol 42(9):896–901
12. de la Iglesia R, Lopez-Legarrea P, Crujeiras AB, Pardo M, Casanueva FF, Zulet MA, Martinez JA (2014) Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clin Endocrinol 81(10):306–311
13. Crujeiras AB, Pardo M, Arturo RR, Navas-Carretero S, Zulet MA, Martinez JA, Casanueva FF (2014) Longitudinal variation of circulating irisin after an energy restriction-induced weight loss and following weight regain in obese men and women. Am J Hum Biol 26:198–207
14. Huang W, Liu Y, Xu H, Zhu H, Guan J, Yi H, Zou J (2020) Association of the serum irisin level with obstructive sleep apnea: a body mass index- and physical activity matched study. Endocr J 67(6):607–612
15. Campolo J, Corradi E, Rizzardi A, Parolini M, Dellanoce C, Di Guglielmo ML, Tarlari P, Cattaneo M, Trivella MG, De Maria R (2020) Irisin and markers of metabolic derangement in non-diabetic Caucasian subjects with stage I-II obesity during early aging. PLoS ONE 15(2):e0229152
16. Löffler D, Müller U, Scheuermann K, Friebe D, Gesing J, Bieltz J, Erbs S, Landgraf K, Wagner IV, Kiess W, Körner A (2015) Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab 100:1289–1299
17. Abe T, Dankel SJ, Loenneke JP (2019) Body fat loss automatically reduces lean mass by changing the fat-free component of adipose tissue. Obesity 27(3):357–358
18. Leidy HJ, Carnell NS, Mattes RD, Campbell WW (2007) Higher protein intake pre-serves lean mass and satiety with weight loss in pre-obese and obese women. Obesity (Silver Spring) 15(2):421–429
19. Human energy requirements: report of a joint FAO/WHO/UNU Expert Consultation (2005) Food Nutr Bull 26(1):166
20. Biernat E, Stupicki R, Gajewski KA (2007) International questionnaire of physical activity (IPAQ)—Polish version. Wych Fiz Sport 51(1):47–54 (article in Polish)
21. Cule E, De Iorio M (2013) Ridge regression in prediction problems: automatic choice of the ridge parameter. Genet Epidemiol 37(7):704–714
22. Ma X, Liu S, Zhang J, Dong M, Wang Y, Wang M, Xin Y (2020) Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol 20(1):10
23. Cheung AS, de Rooy C, Hoermann R, Gianatti EJ, Hamilton EJ, Roff G, Zajac JD, Grossmann M (2016) Correlation of visceral adipose tissue measured by Lunar Prodigy dual X-ray absorptiometry with MRI and CT in older men. Int J Obesity 40:1325–1328
24. Rospieszcz S, Dermyshi D, Müller-Peltzer K, Strauch K, Bamberg F, Peters A (2020) Association of serum uric acid with visceral, subcutaneous and hepatic fat quantified by magnetic resonance imaging. Sci Rep 10:442
25. Cox CE (2017) Role of physical activity for weight loss and weight maintenance. Diabetes Spectr 30(3):157–160
26. Hernández-Reyes A, Câmara-Martos F, Molina-Luque R, Romero-Saldaña M, Molina-Recio G, Moreno-Rojas R (2019) Changes in body composition with a hypocaloric diet combined with sedentary, moderate and high-intensity physical activity: a randomized controlled trial. BMC Women’s Health 19:167
27. Liu J, Fox CS, Hickson DA, May WD, Hairson KG, Carr JJ, Taylor HA (2010) Impact of abdominal visceral and subcutaneous adipose tissue on cardiometabolic risk factors: the Jackson Heart Study. J Clin Endocrinol Metab 95(12):5419–5426
28. Hyun UM, Kyoung HH, Seung JH, Hae JK, Dae J (2019) The association of adiponectin and visceral fat with insulin resistance and β-cell dysfunction. J Korean Med Sci 34(1):e7
29. Christiansen T, Paulsen S, Bruun J, Overgaard K, Ringgaard S, Pedersen SB, Positano V, Richelsen B (2009) Comparable reduction of the visceral adipose tissue depot after a diet-induced weight loss with or without aerobic exercise in obese subjects: a 12-week randomized intervention study. Eur J Endocrinol 160(5):759–767
30. Zhang H, Tong T, Qiu W, Zhang X, Zhou S, Liu Y, He Y (2017) Comparable effects of high-intensity interval training and prolonged continuous exercise training on abdominal visceral fat reduction in obese young women. J Diabetes Res 2017:5071740
31. Ohkawara K, Tanaka S, Miyachi M, Ishikawa-Takata K, Tabata I (2007) A dose–response relation between aerobic exercise and visceral fat reduction: systematic review of clinical trials. Int J Obesity 31:1786–1797
32. Midorikawa T, Ohta M, Torii S, Sakamoto S (2019) Lean soft tissue mass measured using dual-energy x-ray absorptiometry is an effective index for assessing change in leg skeletal muscle mass following exercise training. J Clin Densitom 21(3):394–398
33. Hioki M, Kachibara N, Koike T, Saito A, Shimakawa K, Sakakibara H, Oshida Y, Akima H (2020) Age-related changes in muscle volume and intramuscular fat content in quadriceps femoris and hamstrings. Exp Gerontol 132:110834
34. Waters DL (2019) Intermuscular adipose tissue: a brief review of etiology, association with physical function and weight loss in older adults. Ann Geriatr Med Res 23(1):3–8
35. Ferrara D, Montecucco F, Dallegri F, Carbone F (2019) Impact of abdominal obesity and visceral fat on cardiometabolic disease. J Cell Physiol 234(12):21630–21641
36. Pedersen SB, Positano V, Richardsen B (2009) Comparable reduction of the visceral adipose tissue depot after a diet-induced weight loss with or without aerobic exercise in obese subjects: a 12-week randomized intervention study. Eur J Endocrinol 160(5):759–767
37. Romero-Saldaña M, Molina-Recio G, Moreno-Rojas R (2019) Changes in body composition with a hypocaloric diet combined with sedentary, moderate and high-intensity physical activity: a randomized controlled trial. BMC Women’s Health 19:167
38. Midorikawa T, Ohta M, Torii S, Sakamoto S (2019) Lean soft tissue mass measured using dual-energy x-ray absorptiometry is an effective index for assessing change in leg skeletal muscle mass following exercise training. J Clin Densitom 21(3):394–398
39. Hioki M, Kachibara N, Koike T, Saito A, Shimakawa K, Sakakibara H, Oshida Y, Akima H (2020) Age-related changes in muscle volume and intramuscular fat content in quadriceps femoris and hamstrings. Exp Gerontol 132:110834
40. Waters DL (2019) Intermuscular adipose tissue: a brief review of etiology, association with physical function and weight loss in older adults. Ann Geriatr Med Res 23(1):3–8
41. Ferrara D, Montecucco F, Dallegri F, Carbone F (2019) Impact of different ectopic fat depots on cardiovascular and metabolic diseases. J Cell Physiol 234(12):21630–21641
42. Seimon RV, Wild-Taylor AL, Keating SE, McClintock S, Harper C, Gibson AA, Johnson NA, Fernando HA, Markovic TP, Center JR, Franklin J, Liu PY, Grieve SM, Lagopoulos J, Caterson ID, Byrne NM, Sainsbury A (2019) Effect of weight loss via severe vs moderate energy restriction on lean mass and body composition among postmenopausal women with obesity: the TEMPO Diet Randomized Clinical Trial. JAMA Netw Open 2(10):e1913733
43. Buscemi S, Corleo D, Vasto S, Buscemi C, Massenti MF, Nuzzo D, Lucisano G, Barile AM, Rosafo G, Maniaci V, Giordano C (2018) Factors associated with circulating concentrations of irisin in the general population cohort of the ABCD study. Int J Obes (Lond) 42(3):398–404
38. Qiu S, Cai X, Sun Z, Schumann U, Zügel M, Steinacker JM (2015) Chronic exercise training and circulating irisin in adults: a meta-analysis. Sports Med 45(11):1577–1588
39. Elizondo-Montemayor L, Mendoza-Lara G, Gutierrez-DelBosque G, Peschard-Franco M, Nieblas B, Garcia-Rivas G (2018) Relationship of circulating irisin with body composition, physical activity, and cardiovascular and metabolic disorders in the pediatric population. Int J Mol Sci 19(12):3727
40. Qiu S, Cai X, Yin H, Zügel M, Sun Z, Steinacker JM, Schumann U (2016) Association between circulating irisin and insulin resistance in non-diabetic adults: a meta-analysis. Metabolism 65:825–834
41. Albrecht E, Schering L, Buck F, Vlach K, Schober HC, Drevon CA, Maak S (2020) Irisin: still chasing shadows. Mol Metab 34:124–135

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.